U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07808515) titled 'A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)' on Sept. 01.
Brief Summary: This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
The study is looking at:
* What side effects cemiplimab, alone or in a combination treatment, might cause
* How well cemiplimab, alone or in a combination treatment, works
* How cemiplimab, alone or in a combination treatment could affect the immune system, which can help rese...